Quantitative-imaging in Cardiac Transthyretin Amyloidosis (I-CARE)

University of Edinburgh

Status: Enrolling

Conditions: ATTR-CM

Treatments: Radiation: 18F-fluoride PET

Study type: Observational

Funder types: Other

Identifiers

NCT05776212

202000469

2020-003350-72 (EudraCT Number)

Details and patient eligibility

About

Transthyretin amyloid cardiomyopathy (ATTR-CM), is a heart muscle disease that's stops the heart muscle working properly. With an ageing population, it is increasingly common but untreated, it has a poor prognosis. Several novel expensive treatments have become available, although we do not understand exactly how they work and why some patients respond, and others do not. The challenge is to develop better methods for monitoring the effects of these treatments, maximizing their benefits and cost-effectiveness. In I-CARE we aim to bring a new imaging technique, named 18F-fluoride PET, to the clinic and thereby improve the care of patients with ATTR-CM.

Hypotheses:

1. A delayed imaging protocol and state-of-the-art PET motion correction will optimise 18F-fluoride imaging in ATTR-CM and provide a clear threshold in myocardial TBR values for the diagnosis of ATTR-CM.
2. Optimised 18F-fluoride PET will provide a quantitative marker of the ATTR-CM burden that will allow disease progression and treatment response to be tracked.
3. Myocardial 18F-fluoride TBR values will reduce in patients responding to tafamidis treatment and increase in non-responders and patients not receiving therapy

Full description

Studies have shown that there is calcium deposition in the heart muscle in ATTR-CM but exactly how this happens is not completely understood. Tafamidis, a new drug treatment, has shown improved outcomes for patients with ATTRCM by reducing hospitalisations and improving survival but the mechanism of action of Tafamidis is also not clearly understood yet. 18F-Fluoride PET/CT offers the opportunity to study this phenomenon of calcium deposition in ATTR-CM in more detail and study and track response to the new drug treatment. This will also provide an opportunity to investigate whether tafamidis therapy reduces calcium deposition in the heart muscle associated with ATTR-CM.

We have designed the study specifically to answer our research questions as best as possible, whilst keeping burdens to the patients at a minimum.

To the best of our knowledge this will be the first human study to utilise this imaging technique to assess and track response to the new drug treatment in ATTR-CM. We hope that it will provide major insights in to complex interactions at play, that could drive forward the development of novel therapeutic strategies for patients with ATTR-CM.

Enrollment: 140 estimated patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Completion of informed consent
• Age > 40 years for patients with ATTR or AL cardiac amyloidosis and age >30 years for patients with HCM
• ATTR cardiac amyloid according to Expert Consensus Recommendations
• AL amyloidosis according to Expert Consensus Recommendations
• Hypertrophic cardiomyopathy according to European Society of Cardiology guidelines

Exclusion criteria

• Inability or unwilling to give informed consent
• Women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial.
• Renal dysfunction (eGFR ≤30 mL/min/1.73m2)
• NYHA Class IV heart failure
• Patients with atrial fibrillation and poor rate control.
• Contraindications to MR
• Previous history of contrast allergy of adverse reactions (gadolinium)
• Contraindications to tafamidis therapy

Trial design

140 participants in 4 patient groups

Work package 1 - Optimisation of 18F-fluoride PET in ATTR-CM

Description:

Optimise 18F-fluoride PET imaging of ATTR-CM with increased myocardial tissue to background ratio (TBR) uptake values to provide a state-of-the-art imaging modality for use in the other work packages. (n=15, ATTR-CM subjects)

Treatment:

Radiation: 18F-fluoride PET

Work package 2 - Differentiation ATTR-CM from phenocopies

Description:

Establish the optimised 18F-fluoride TBR threshold that best differentiates ATTR-CM (n=100) from phenocopies (subjects with light chain amyloidosis, n=20 and subjects with hypertrophic cardiomyopathy, n=20).

Treatment:

Radiation: 18F-fluoride PET

Work package 3 - In vivo calibration of 18F-fluoride PET

Description:

In vivo calibration of 18F-fluoride PET as a marker of the myocardial ATTR burden, calibrating optimised TBR values against the current imaging standard cardiac magnetic resonance imaging extracellular volume. (Subjects with ATTR-CM, n=100)

Treatment:

Radiation: 18F-fluoride PET

Work package 4 - Disease progression and treatment response

Description:

Establish ability of 18F-fluoride PET to track disease progression and treatment response in ATTR-CM at one year follow up. (Subjects with ATTR-CM, n=100)

Treatment:

Radiation: 18F-fluoride PET